Corteria Pharmaceuticals develops first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonists to treat worsening and acute decompensated heart failure, targeting specific patient subpopulations with high unmet medical needs. The company employs innovative patient stratification methods to identify individuals most likely to benefit from its therapies, addressing the critical issue of fluid retention and pulmonary congestion in heart failure patients.
Funding
$88.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
JCFounders
Product
Problem
Heart failure, affecting over 60 million individuals globally, is characterized by pulmonary congestion, often leading to unscheduled hospitalizations. Current treatments do not always address the underlying neuro-endocrine imbalances that cause excessive fluid retention, especially in patients with pre-existing chronic kidney disease. Both acute decompensated heart failure and the worsening of chronic heart failure symptoms represent significant unmet medical needs.
Solution
Corteria Pharmaceuticals develops first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonists to treat worsening and acute decompensated heart failure. Their approach involves innovative patient stratification methods to identify individuals most likely to benefit from CRF2-targeted therapies. The company's lead compounds, including COR-1167 and COR-1389, aim to address fluid retention and pulmonary congestion by modulating neuro-endocrine hormones responsible for renal sodium and water reabsorption. Preclinical data suggests that CRF2 agonism can improve cardiac and pulmonary function in heart failure models.
Target Audience
The primary target audience includes patients with worsening and acute decompensated heart failure, right heart failure, and those with co-existing conditions like sarcopenia and obesity.
Features
- COR-1167: A CRF2 peptide agonist being evaluated in a first-in-human study for worsening heart failure.
- COR-1389: A CRF2 agonist showing promise in preclinical models of right heart failure, improving cardiac and pulmonary function.
- Innovative patient stratification methods to identify responders to CRF2-targeted therapies.
- Focus on addressing the neuro-endocrine imbalances that contribute to fluid retention in heart failure.